![]() Severe or life-threatening neutropenia may occur. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. This indication is approved under accelerated approval based on tumor response rate and duration of response. Locally advanced or metastatic urothelial cancer (mUC) who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.Unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.TRODELVY® (sacituzumab govitecan-hziy) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with: Please download the resource guide below to assist you with proper coding to help optimize reimbursement support. Gilead and its agents make no guarantee regarding reimbursement for any service or item.Ĭoverage, billing, and coding requirements for TRODELVY may vary by plan and patient. Its agents, will contact the patient directly regarding the application process. The foundation will determine the patient’s eligibility for co-pay or co-insurance assistance based on their own criteria and, completely independent of Gilead and Managers can provide information about any available foundations. If co-pay assistance needs are identified, the Case Case Managers can help patients assess their high-level eligibility for possible coverage for TRODELVY through an independent co-pay assistance foundation. ‡Patients with Medicare or other government insurance who need assistance with cost-share requirements for TRODELVY may be eligible for co-pay or co-insurance assistance through an independent co-payĪssistance foundation.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |